1. Philip J. Ditchfield Manager, Contracts & Licensing GlaxoSmithKline Data Mining and the Pharmaceutical Industry

2. Enabling People to Do More, Feel Better and Live Longer Large British Pharmaceutical and Healthcare Company £28.4 billion turnover £3.96 billion spent on R&D ~ 96,000 staff / 100 countries Major research centres in UK, US, China and Belgium Researching HIV/AIDS, malaria, tuberculosis, mental health, asthma, diabetes, cardiovascular, digestive diseases and cancer Also manufacture medicines and vaccines Mission to improve the quality of human life

3. The R&D Process ~12 – 14 years of research ~ £600 million per drug 38 Discovery Performance Units 26 Medicine Development Teams Challenging highly regulated environment Goal to deliver more products of value To innovate; new ways of researching and collaborating, e.g.: Open science – UK’s first open innovation biomed campus: Stevenage Science Park We also need to change the way we use data

4. The Data Challenge As an industry we generate endless quantities of data Published biomed literature doubles in volume every seven years Subscribe to thousands of electronic journals, books and data sources Respect publishers’ business and IP Evolving direct (publisher) licenses Indirect licenses (CLA and CCC) Concentrate on small pieces Consume information manually

5. Benefits of Data Mining 7,000 diseases world-wide; cure only 80 Need to: Explore alternative methods of analysing & digesting large volumes of information Use technology effectively – to automate manual processes Data mining will help: Find the nuggets See hidden patterns For data mining to work: Breadth and depth of data Without unnecessary restrictions Legal framework to support innovation and R&D in the UK

6. Any questions? Thank you